Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Novo Nordisk A/S
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
BerGenBio ASA
IRCCS San Raffaele
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
University of Washington
University of Washington
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Duke University
Bio-Path Holdings, Inc.
St. Jude Children's Research Hospital
Pfizer
Baylor College of Medicine
Aileron Therapeutics, Inc.
University of Maryland, Baltimore
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Washington
St. Jude Children's Research Hospital
Barbara Ann Karmanos Cancer Institute
Hospital Israelita Albert Einstein
Stichting Hemato-Oncologie voor Volwassenen Nederland
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Children's Oncology Group
University of Chicago
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Baylor Research Institute
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
National Cancer Institute (NCI)
Weill Medical College of Cornell University
Barbara Ann Karmanos Cancer Institute